Sosei Heptares Adds Lilly To Big Pharma Client List
Inks Diabetes And Metabolic Diseases Deal
The Japan-UK group is ending the year on a high, banking $37m upfront from a pact with Eli Lilly that will focus on finding small molecules which modulate G protein-coupled receptor (GPCR) targets.
